Cross-Sector entity
Codexis is the most frequent co-covered peer, appearing in 5 of the 16 tracked stories. Across a 183-day span, the pace is roughly 0.6 stories per week. The busiest single day carried 5. acquisition accounts for 4 of the 16 tracked stories, while 7 other categories carry the remainder.
16 verified stories tracked
Last mentioned: 5d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 81 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Codexis is the most frequent co-covered peer, appearing in 5 of the 16 tracked stories. Across a 183-day span, the pace is roughly 0.6 stories per week. The busiest single day carried 5. acquisition accounts for 4 of the 16 tracked stories, while 7 other categories carry the remainder. Each carries 19.4 original sources on average. This profile follows 16 Cross-Sector stories mentioning Merck across the period from February 19, 2026 to August 20, 2026. Negative sentiment appears in 0% of the tracked stories.
Computed from the 16 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Merck. Shared-story counts are live from our verified record — not editorial picks.
Keytruda Patent Expiration
The primary patent for Merck's blockbuster drug Keytruda expires, opening the door for biosimilars.
NXT 41X Launch
Anticipated commercial launch of Elutia's next-gen drug-eluting biomaterial.
Pipeline Integration
Merck integrates Terns' small-molecule oncology candidates into its global R&D infrastructure.
TERN-701 Data Readout
Key clinical milestones for the leukemia candidate are expected to drive valuation.
Expected Closing
Anticipated completion of the acquisition following regulatory and shareholder approvals.
FDA Approves Lipfendra
The FDA approved Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor, for adults with hypercholesterolemia including inherited forms, based on Phase 3 CORALreef trials showing 56-59% LDL-C reduction.
Expected Closing
The deal is anticipated to close following regulatory approvals and Terns shareholder vote.
Bumble 2.0 Launch
Targeted launch of AI-enabled platform experience.
Acquisition Announced
Merck and Terns Pharmaceuticals announce a definitive $6.7 billion merger agreement.
Analyst Sentiment Review
Major firms maintain ratings, citing steady execution of the strategic pivot.
Analyst Upgrade
Wall Street Zen upgrades CDXS rating following financial results.
2026 Guidance Issued
Management outlines $72M-$76M revenue target driven by ECO Synthesis.
Codexis CDMO Expansion
Announced three major CDMO agreements with Bachem, Nitto Avecia, and Axolabs.
Q4 2025 Earnings Release
Codexis reports significant beats on both top and bottom lines.
TD Cowen Conference
CEO touts ECO Synthesis push and 2026 inflection targets.
Elutia FDA Milestone
Expected FDA submission for NXT 41X product line.
Elutia Divestiture
Completed $88M sale of bioenvelope business to Boston Scientific.
Prometheus Acquisition
Merck buys Prometheus Biosciences for $10.8 billion to bolster its immunology pipeline.
Acceleron Acquisition
Merck acquires Acceleron Pharma for $11.5 billion to expand in cardiovascular disease.
For finance readers, Aug. 19 was a case study in cross-asset relief: Treasury buyback news pulled the 30-year yield off its highest since 2007, feeding a 0.21% S&P 500 gain, while a more than 137% Moderna surge drove healthcare to a record 2.9% gain. The support for risk appetite masks a hawkish Fed minutes message and an unresolved long-term rate threat to AI-heavy valuations.
Moderna's mRNA cancer therapy readout sent its shares up as much as 177%, driving a 2.9% record gain in the S&P 500 healthcare sector amid easing Treasury yields. The rally lifted peers including Merck, BioNTech and Novavax, but macro rate worries persist.
Source: Sph Media (sg) · Reuters (my)
The FDA approved the first oral PCSK9 inhibitor, Lipfendra, demonstrating a 59% LDL reduction in trials. The pill form removes injection barriers and is priced lower than existing injectables, potentially improving adherence and access for patients with high cholesterol.
Merck won FDA approval for Lipfendra, a small-molecule oral PCSK9 inhibitor that achieved 56-59% LDL-C reductions in Phase 3. This breakthrough in oral delivery challenges the dominance of injectable biologics from Amgen and Sanofi/Regeneron.
Source: mix969.iheart.com · rock1053.iheart.com
Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion, securing a late-stage leukemia candidate to diversify its oncology portfolio. The deal provides Merck with TERN-701, a promising treatment for chronic myeloid leukemia, as it prepares for the 2028 patent expiration of its blockbuster drug Keytruda.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising allosteric BCR-ABL inhibitor for leukemia. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug, Keytruda.
Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion in cash to bolster its oncology pipeline ahead of the 2028 patent expiration for its blockbuster drug, Keytruda. The deal centers on TERN-701, a promising leukemia treatment that positions Merck to compete directly with established players like Novartis.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion in cash, a strategic move to diversify its oncology pipeline. The deal centers on Terns' promising leukemia candidate, TERN-701, as Merck prepares for the 2028 patent expiration of its blockbuster immunotherapy, Keytruda.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, a strategic move designed to diversify its oncology portfolio. The acquisition comes as Merck prepares for the impending patent expiration of its top-selling cancer immunotherapy, Keytruda, later this decade.
Source: abcnews.com · clickorlando.com
Codexis reported a significant Q4 2025 earnings beat, driven by its ECO Synthesis platform and expanding CDMO partnerships. Despite a raised 2026 revenue outlook and a surprise GAAP profit, analyst sentiment remains largely unchanged as the market awaits further commercial validation of its RNA manufacturing technology.
Codexis (CDXS) has maintained steady analyst sentiment following a strong Q4 2025 performance that exceeded revenue and earnings expectations. The company’s strategic pivot toward its ECO Synthesis platform for RNA manufacturing is gaining commercial traction, supported by a 2026 revenue target of $72M–$76M.
Source: finance.yahoo.com · insidermonkey.com
Wall Street Zen has upgraded the stock ratings for Codexis (CDXS) and Enovis (ENOV), signaling increased confidence in their long-term strategic pivots. The upgrades follow robust quarterly performances and the unveiling of ambitious 2026 revenue targets driven by high-margin technological innovations.
Source: dailypolitical.com · themarketsdaily.com
Q4 2025 earnings for specialized biotech firms reveal a sector-wide shift toward high-margin manufacturing and strategic divestitures. While Codexis capitalizes on its Merck partnership and ECOsynthesis platform, Elutia has cleared its debt through an $88 million divestiture to Boston Scientific.
The Q4 2025 earnings cycle for mid-cap healthcare and life sciences firms reveals a strategic shift toward high-margin AI integration and portfolio streamlining. Companies like Elutia and Codexis are leveraging divestitures and technology transfers to shore up balance sheets, while AI-driven productivity gains are becoming a primary differentiator in clinical and operational workflows.
Merck and Mayo Clinic have launched a strategic R&D collaboration to integrate artificial intelligence into drug discovery and precision medicine. The partnership combines Mayo Clinic's vast clinical data with Merck's therapeutic expertise to identify novel drug targets and personalize patient care.
Merck and Mayo Clinic have entered a multi-year research and development collaboration to leverage artificial intelligence for drug discovery and personalized patient care. The partnership integrates Merck's pharmaceutical expertise with Mayo Clinic's clinical data and AI capabilities to accelerate the development of targeted therapies.
Source: Yahoo Finance · Mayo Clinic News Network
